Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Consensus Recommendation of “Buy” by Analysts

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have received a consensus rating of “Buy” from the ten research firms that are presently covering the firm, Marketbeat reports. Ten investment analysts have rated the stock with a buy rating. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $73.38.

Several equities analysts recently weighed in on the company. BMO Capital Markets assumed coverage on Jasper Therapeutics in a research note on Friday, December 6th. They issued an “outperform” rating and a $63.00 price target on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Jasper Therapeutics in a research report on Monday, September 9th. JMP Securities reaffirmed a “market outperform” rating and set a $70.00 price target on shares of Jasper Therapeutics in a research report on Tuesday, October 15th. Royal Bank of Canada reiterated an “outperform” rating and issued a $68.00 price target on shares of Jasper Therapeutics in a report on Monday, December 23rd. Finally, HC Wainwright reissued a “buy” rating and set a $65.00 price objective on shares of Jasper Therapeutics in a research note on Thursday, October 24th.

Institutional Trading of Jasper Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets lifted its stake in shares of Jasper Therapeutics by 208.6% during the third quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock worth $47,000 after purchasing an additional 1,698 shares in the last quarter. Wolff Wiese Magana LLC purchased a new stake in shares of Jasper Therapeutics during the 3rd quarter valued at about $59,000. MetLife Investment Management LLC lifted its position in Jasper Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock worth $129,000 after acquiring an additional 3,873 shares in the last quarter. Jane Street Group LLC purchased a new position in Jasper Therapeutics in the 3rd quarter worth approximately $251,000. Finally, Rhumbline Advisers purchased a new position in Jasper Therapeutics in the 2nd quarter worth approximately $300,000. 79.85% of the stock is owned by hedge funds and other institutional investors.

Jasper Therapeutics Stock Down 8.6 %

Shares of Jasper Therapeutics stock opened at $19.27 on Wednesday. The firm has a market cap of $289.07 million, a PE ratio of -4.07 and a beta of 2.18. Jasper Therapeutics has a fifty-two week low of $6.50 and a fifty-two week high of $31.01. The business’s fifty day moving average is $22.07 and its two-hundred day moving average is $20.50.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.